Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Dac g 1 is a major group 1 allergen derived from the pollen of Dactylis glomerata, commonly known as orchard grass or cocksfoot. Biologically, it functions as a beta-expansin, a protein that facilitates plant reproduction by loosening cell walls to allow pollen tube penetration. In susceptible individuals, Dac g 1 is a potent trigger for Type I hypersensitivity, contributing significantly to symptoms of hay fever, allergic rhinitis, and asthma. It is recognized by IgE antibodies in approximately 95% of grass pollen-allergic patients, making it a critical component in both diagnosis and treatment. Therapeutic intervention typically involves allergen-specific immunotherapy (AIT) using standardized extracts, such as Oralair, to desensitize the immune system and promote long-term clinical tolerance.
Allergen-specific immunotherapy (AIT) involves the administration of increasing doses of the allergen to induce immunological tolerance, characterized by a shift from a Th2 to a Th1/Treg immune response and the production of allergen-specific IgG4 blocking antibodies.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Dactylis glomerata allergen 1 (Dac g 1).